Download PDF
Thromb Haemost 1991; 65(02): 144-148
DOI: 10.1055/s-0038-1647473
Original Article
Schattauer GmbH Stuttgart

An Analysis of the Activators of Single-Chain Urokinase-Type Plasminogen Activator (scu-PA) in the Dextran Sulphate Euglobulin Fraction of Normal Plasma and of Plasmas Deficient in Factor XII and Prekallikrein

D J Binnema
The Gaubius Institute TNO, Leiden, The Netherlands
,
G Dooijewaard
The Gaubius Institute TNO, Leiden, The Netherlands
,
P N C Turion
The Gaubius Institute TNO, Leiden, The Netherlands
› Author Affiliations
Further Information

Publication History

Received: 12 July 1990

Accepted after revision 12 September 1990

Publication Date:
02 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

An analysis was made of the various possible activators of single-chain urokinase-type plasminogen activator (scu-PA) in the dextran sulphate euglobulin fraction (DEF) of human plasma. scu-PA activators were detected in an assay system in which the substrate scu-PA, in physiological concentration (50 pM), was immuno-immobilized. After activation of the immobilized scu-PA for a certain period of time the activity of the generated amount of immuno-immobilized two-chain u-PA was determined with plasminogen and the chromogenic substrate S-2251. The scu-PA activator activity (scuPA-AA) in the DEF of plasmas deficient in factor XII or prekallikrein was about half of that in the DEF of normal plasma. Separation of scuPA-AA in the DEF by gel chromatography showed to major peaks, one eluting with an apparent Mr of 500,000 and the other around Mr 100,000. The former peak, which coincided with the activity peak of the kallikrein-kininogen complex, was absent in the DEF of plasma depleted of prekallikrein and therefore was identified as kalli-krein. The latter peak was still present in the depleted plasma and most likely represents plasmin, because its scuPA-AA coincided with the activity peak of plasmin and could be fully inhibited by antibodies raised against human plasminogen. It is concluded that plasmin and the contact-activation factor kallikrein each contribute for about 50% to the scuPA-AA in the DEF. Compared on a molar basis, however, plasmin was found to be almost 1,000 times more effective than kallikrein, and we conclude, therefore, that in vivo plasmin is the primary activator of scu-PA and the role of the contact system is of secondary importance.

 

  • REFERENCES

  • 1 Bachmann F. Fibrinolysis. In: Thrombosis and Haemostasis Ver-straete M, Vermijlen J, Lijnen HR, Amout J. (eds) International Society on Thrombosis and Haemostasis and Leuven University Press; Leuven: 1987: 227-263
  • 2 Wijngaards G, Kluft C, Groeneveld E. Demonstration of urokinase-related fibrinolytic activity in human plasma. Br J Haematol 1982; 51: 165-169
    CrossrefPubMedGoogle Scholar
  • 3 Wun T-C, Schleuning WD, Reich E. Isolation and characterization of urokinase from human plasma. J Biol Chem 1982; 257: 3276-3283
    PubMedGoogle Scholar
  • 4 Tissot JD, Schneider P, Hauert J, Ruegg M, Kruithof EKO, Bachmann F. Isolation from human plasma of a plasminogen activator identical to urinary high molecular weight urokinase. J Clin Invest 1982; 70: 1320-1323
    CrossrefPubMedGoogle Scholar
  • 5 Wun T-C, Ossowski L, Reich E. A proenzyme form of human urokinase. J Biol Chem 1982; 257: 7262-7268
    PubMedGoogle Scholar
  • 6 Husain SS, Gurewich V, Lipinski B. Purification and partial characterization of a single-chain high-molecular-weight form of urokinase from human urine. Arch Biochem Biophys 1983; 220: 31-38
    CrossrefPubMedGoogle Scholar
  • 7 Dooijewaard G, Van Iersel JJL, Brommer EJP. Quantitation of pro-UK, and UK. Inhibitor levels in plasma of patients and healthy man. In: Abstracts of the Eighth International Congress on Fibrinolysis Binder BR. (ed) Vienna 1986. Churchill Livingstone; Edinburgh: 1986: 142
  • 8 Nielsen LS, Hansen JG, Skriver L, Wilson EL, Kaltoft K, Zeuthen J, Danϕ K. Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. Biochemistry 1982; 21: 6410-6415
    CrossrefPubMedGoogle Scholar
  • 9 Eaton DL, Scott RW, Baker JB. Purification of human fibroblast urokinase proenzyme and analysis of its regulation by proteases and protease nexin. J Biol Chem 1984; 259: 6241-6247
    PubMedGoogle Scholar
  • 10 Gurewich V, Panell R. Pro-urokinase (PUK) – Characterization of its enzymatic activation. Thromb Haemostas 1985; 54: 102
    PubMedGoogle Scholar
  • 11 Kasai S, Arimura H, Nishida M, Suyama T. Proteolytic cleavage of single-chain pro-urokinase induces conformational change which follows activation of the zymogen and reduction of its high affinity for fibrin. J Biol Chem 1985; 260: 12377-12381
    PubMedGoogle Scholar
  • 12 Ichinose A, Fujikawa K, Suyama T. The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. J Biol Chem 1986; 261: 3486-3489
    PubMedGoogle Scholar
  • 13 Miles LA. Mechanisms of intrinsic fibrinolysis. Thesis, University of California; San Diego, CA: 1982
    Google Scholar
  • 14 Miles LA, Rothschild ZS, Griffin JH. Dextran sulphate-dependent fibrinolytic activity in whole human plasma. In: Progress in Fibrinolysis Davidson JF. et al. (eds) Churchill Livingstone; Edinburgh: 1983. 6 58-61
  • 15 Huisveld IA, Hospers JEH, Van Heeswijk GM, Bemick MJE, Erich WBM, Bouma BN. Contribution of contact activation factors to urokinase-related fibrinolytic activity in whole human plasma. Thromb Haemostas 1985; 54: 102
    PubMedGoogle Scholar
  • 16 Hauert J, Nicoloso G, Schleunig W-D, Bachmann F, Schapira M. Plasminogen activators in dextran sulphate-activated euglobulin fractions: a molecular analysis of factor XII- and prekallikrein-dependent fibrinolysis. Blood 1989; 73: 994-999
    PubMedGoogle Scholar
  • 17 Binnema DJ, Dooijewaard G, Van IerselJJL, Turion PNC, Kluft C. The contact system-dependent plasminogen activator from human plasma: identification and characterization. Thromb Haemostas 1990; 64: 390-397
    PubMedGoogle Scholar
  • 18 Kluft C, Wijngaards G, Jie AFH. Intrinsic plasma fibrinolysis: Involvement of urokinase-related activity in the factor XH-indepen-dent plasminogen proactivator pathway. J Lab Clin Med 1984; 103: 408-419
    PubMedGoogle Scholar
  • 19 Binnema DJ, Dooijewaard G. Involvement of factor XII (F XII) and prekallikrein (PKK) in the activation of urokinase (UK)-related proteins in human plasma. Thromb Haemostas 1987; 58: 137
    PubMedGoogle Scholar
  • 20 Kluft C, Dooijewaard GS, Emeis JJ. 1987 Role of the contact system in fibrinolysis. Semin Thromb Hemostas 1987; 13: 50-68
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Binnema DJ, Dooijewaard G, Turion PNC. Inventory of prourokinase activating components in the dextran sulphate euglobulin fraction of plasma. Fibrinolysis 1988; 2 (Suppl. 01) 48 Abstr 107
    PubMedGoogle Scholar
  • 22 Kluft C, Brakman P, Veldhuyzen-Stolk EC. 1976 Screening of fibrinolytic activity in plasma euglobulin fractions on the fibrin plate. In: Progress in Chemical Fibrinolysis and Thrombolysis Davidson JF. et al. (eds) Raven Press; New York: 1976. 2 57-65
  • 23 Kluft C. Studies on the fibrinolytic system in human plasma: Quantitative determination of plasminogen activators and proactivators. Thromb Haemostas 1979; 41: 365-383
    PubMedGoogle Scholar
  • 24 Kluft C. Synthetic substrates for the assay of prekallikrein and factor XII. In: Methods in Enzymology Di Sabato G. (ed) Academic Press; San Diego, CA: 1988. 163 170-179
  • 25 Kluft C, Trumpi-Kalshoven MM, Jie AFH, Veldhuyzen-Stolk EC. Factor XH-dependent fibrinolysis: a double function of plasma kallikrein and the occurrence of a previously undescribed factor XII-and kallikrein-dependent plasminogen proactivator. Thromb Haemostas 1979; 41: 756-773
    PubMedGoogle Scholar
  • 26 Binnema DJ, Van IerselJJL, Dooijewaard G. Quantitation of urokinase antigen in plasma and culture media by use of an ELISA. Thromb Res 1986; 43: 569-577
    CrossrefPubMedGoogle Scholar
  • 27 Verheijen JH, Mullaart E, Chang GTG, Kluft C, Wijngaards G. A simple sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb Haemostas 1982; 48: 266-269
    PubMedGoogle Scholar
  • 28 Friberger P, Knos M, Gustavsson S. Methods for determination of plasmin, antiplasmin and plasminogen by means of substrate S-2251. Haemostasis 1978; 7: 138-45
    PubMedGoogle Scholar
  • 29 Exner T, Cotton B, Howden M. Detection of specific proenzyme activators in snake venoms by a new immunoadsorbent-chromogenic substrate method. Biochim Biophys Acta 1985; 832: 351-356
    CrossrefPubMedGoogle Scholar
  • 30 Wojta J, Binder BR, Huber K, Hoover RL. Evaluation of fibrinolytic capacity in plasma during thrombolytic therapy with single (scu-PA) or two-chain urokinase-type plasminogen activator (tcu-PA) by a combined assay system for urokinase type plasminogen activator antigen and function. Thromb Haemostas. 1989; 61: 289-293
    PubMedGoogle Scholar
  • 31 Darras V, Thienpont M, Stump DC, Collen D. Measurement of urokinase-type plasminogen activator (u-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies. Thromb Haemostas 1986; 56: 411-414
    PubMedGoogle Scholar
  • 32 Grϕndahl-Hansen J, Agerlin NS, Munkholm-Larsen P, Bach F, Nielsen LS, Dombemovsky P, Danϕ K. Sensitive and specific enzyme-linked immuno-sorbent assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer. J Lab Clin Med 1988; 111: 42-51
    PubMedGoogle Scholar
  • 33 Blasi F, Vassalli J-D, Danϕ K. Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J Cell Biol 1987; 104: 801-804
    CrossrefPubMedGoogle Scholar
  • 34 Miles LA, Levin EG, Plescia J, Collen D, Plow EF. Plasminogen receptors, urokinase receptors, and their modulation on human endothelial cell. Blood 1988; 72: 628-635
    PubMedGoogle Scholar
  • 35 Barnathan ES, Kuo A, Rosenfeld L, Kariko K, Leski M, Robbiati F, Nolli ML, Henkin J, Cines DB. Interaction of single-chain urokinase-type plasminogen activator with human endothelial cells. J Biol Chem 1990; 265: 2685-2872
    PubMedGoogle Scholar
  • 36 Ellis V, Scully MF, Kakkar W. Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by u937 monocytes. J Biol Chem 1989; 264: 2185-2188
    PubMedGoogle Scholar
  • 37 Stephens RW, Pöllänen J, Tapiovaara H, Leung K-C, Sim P-S, Salonen E-M, Rϕnne E, Behrendt N, Danϕ K, Vaheri A. Activation of prourokinase and plasminogen on human sarcoma cells: A proteolytic system with surface-bound reactants. J Cell Biol 1989; 108: 1987-1995
    CrossrefPubMedGoogle Scholar